Cargando…
Evaluating the Performance of p16(INK4a) Immunocytochemistry in Cervical Cancer Screening
PURPOSE: When used for cervical cancer primary screening, liquid-based cytology (LBC) has a high specificity but a low sensitivity. For histological diagnosis of high-grade lesions, p16(INK4a) immunostaining has proven to be useful. Therefore, our objective was to evaluate the use of p16(INK4a) immu...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524171/ https://www.ncbi.nlm.nih.gov/pubmed/33061601 http://dx.doi.org/10.2147/CMAR.S273079 |
_version_ | 1783588503765909504 |
---|---|
author | Song, Fangbin Du, Hui Xiao, Aimin Wang, Chun Huang, Xia Yan, Peisha Liu, Zhihong Qu, Xinfeng Belinson, Jerome L Wu, Ruifang |
author_facet | Song, Fangbin Du, Hui Xiao, Aimin Wang, Chun Huang, Xia Yan, Peisha Liu, Zhihong Qu, Xinfeng Belinson, Jerome L Wu, Ruifang |
author_sort | Song, Fangbin |
collection | PubMed |
description | PURPOSE: When used for cervical cancer primary screening, liquid-based cytology (LBC) has a high specificity but a low sensitivity. For histological diagnosis of high-grade lesions, p16(INK4a) immunostaining has proven to be useful. Therefore, our objective was to evaluate the use of p16(INK4a) immuno-cytology as a primary screen and a secondary screen after primary high-risk human papillomavirus (hrHPV) screening or LBC screening. METHODS: A total of 1197 cytology slides were immuno-stained using automatic p16(INK4a) staining system (PathCIN(®)p16(INK4a)) in two studies from cervical screening programs. In the primary screening study, 875 slides were randomly selected and analyzed for p16(INK4a). In the secondary screening study, 322 of the remaining slides were chosen by virtue of being HPV 16/18+, other hrHPV+/LBC≥ASC-US, or HPV-negative/LBC ≥LSIL. The sensitivity and specificity for detection of cervical intraepithelial neoplasia 2/3 or worse (CIN2+/CIN3+) were compared based on p16(INK4a), LBC and HPV test results. RESULTS: In combining two studies, there were 431 cases with biopsy pathology. They included 83 cases with CIN2+ and 41 cases with CIN3+. The p16 positivity rate increased with pathologic and cytologic severity (P<0.0001). For primary screening: p16 immuno-cytology was more specific than HPV testing and was similar in sensitivity. Also, p16 immuno-cytology compared favorably with routine LBC (≥ASC-US or ≥LSIL) in sensitivity and specificity. For secondary screening: after LBC screening, “Triaging ASC-US with p16” gave a higher specificity and a similar sensitivity as compared to the “Triaging ASC-US with hrHPV” algorithm. After HPV primary screening, p16 immuno-cytology was more specific than LBC (≥ASC-US); the calculated colposcopy referral rate was also decreased by using p16 immuno-cytology as triage. Triage of “HPV16/18 and p16” had higher specificity and similar sensitivity as compared to triage of “HPV16/18 and LBC ≥ASC-US”. CONCLUSION: For primary screening, p16(INK4a) immuno-cytology compares favorably to routine LBC and HPV testing. p16(INK4a) immunostaining could be an efficient triage to reduce the colposcopy referral rate after primary hrHPV screening or LBC screening. Therefore, p16(INK4a) immuno-cytology may be applicable as a favorable technology for cervical cancer screening. |
format | Online Article Text |
id | pubmed-7524171 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-75241712020-10-14 Evaluating the Performance of p16(INK4a) Immunocytochemistry in Cervical Cancer Screening Song, Fangbin Du, Hui Xiao, Aimin Wang, Chun Huang, Xia Yan, Peisha Liu, Zhihong Qu, Xinfeng Belinson, Jerome L Wu, Ruifang Cancer Manag Res Original Research PURPOSE: When used for cervical cancer primary screening, liquid-based cytology (LBC) has a high specificity but a low sensitivity. For histological diagnosis of high-grade lesions, p16(INK4a) immunostaining has proven to be useful. Therefore, our objective was to evaluate the use of p16(INK4a) immuno-cytology as a primary screen and a secondary screen after primary high-risk human papillomavirus (hrHPV) screening or LBC screening. METHODS: A total of 1197 cytology slides were immuno-stained using automatic p16(INK4a) staining system (PathCIN(®)p16(INK4a)) in two studies from cervical screening programs. In the primary screening study, 875 slides were randomly selected and analyzed for p16(INK4a). In the secondary screening study, 322 of the remaining slides were chosen by virtue of being HPV 16/18+, other hrHPV+/LBC≥ASC-US, or HPV-negative/LBC ≥LSIL. The sensitivity and specificity for detection of cervical intraepithelial neoplasia 2/3 or worse (CIN2+/CIN3+) were compared based on p16(INK4a), LBC and HPV test results. RESULTS: In combining two studies, there were 431 cases with biopsy pathology. They included 83 cases with CIN2+ and 41 cases with CIN3+. The p16 positivity rate increased with pathologic and cytologic severity (P<0.0001). For primary screening: p16 immuno-cytology was more specific than HPV testing and was similar in sensitivity. Also, p16 immuno-cytology compared favorably with routine LBC (≥ASC-US or ≥LSIL) in sensitivity and specificity. For secondary screening: after LBC screening, “Triaging ASC-US with p16” gave a higher specificity and a similar sensitivity as compared to the “Triaging ASC-US with hrHPV” algorithm. After HPV primary screening, p16 immuno-cytology was more specific than LBC (≥ASC-US); the calculated colposcopy referral rate was also decreased by using p16 immuno-cytology as triage. Triage of “HPV16/18 and p16” had higher specificity and similar sensitivity as compared to triage of “HPV16/18 and LBC ≥ASC-US”. CONCLUSION: For primary screening, p16(INK4a) immuno-cytology compares favorably to routine LBC and HPV testing. p16(INK4a) immunostaining could be an efficient triage to reduce the colposcopy referral rate after primary hrHPV screening or LBC screening. Therefore, p16(INK4a) immuno-cytology may be applicable as a favorable technology for cervical cancer screening. Dove 2020-09-25 /pmc/articles/PMC7524171/ /pubmed/33061601 http://dx.doi.org/10.2147/CMAR.S273079 Text en © 2020 Song et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Song, Fangbin Du, Hui Xiao, Aimin Wang, Chun Huang, Xia Yan, Peisha Liu, Zhihong Qu, Xinfeng Belinson, Jerome L Wu, Ruifang Evaluating the Performance of p16(INK4a) Immunocytochemistry in Cervical Cancer Screening |
title | Evaluating the Performance of p16(INK4a) Immunocytochemistry in Cervical Cancer Screening |
title_full | Evaluating the Performance of p16(INK4a) Immunocytochemistry in Cervical Cancer Screening |
title_fullStr | Evaluating the Performance of p16(INK4a) Immunocytochemistry in Cervical Cancer Screening |
title_full_unstemmed | Evaluating the Performance of p16(INK4a) Immunocytochemistry in Cervical Cancer Screening |
title_short | Evaluating the Performance of p16(INK4a) Immunocytochemistry in Cervical Cancer Screening |
title_sort | evaluating the performance of p16(ink4a) immunocytochemistry in cervical cancer screening |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524171/ https://www.ncbi.nlm.nih.gov/pubmed/33061601 http://dx.doi.org/10.2147/CMAR.S273079 |
work_keys_str_mv | AT songfangbin evaluatingtheperformanceofp16ink4aimmunocytochemistryincervicalcancerscreening AT duhui evaluatingtheperformanceofp16ink4aimmunocytochemistryincervicalcancerscreening AT xiaoaimin evaluatingtheperformanceofp16ink4aimmunocytochemistryincervicalcancerscreening AT wangchun evaluatingtheperformanceofp16ink4aimmunocytochemistryincervicalcancerscreening AT huangxia evaluatingtheperformanceofp16ink4aimmunocytochemistryincervicalcancerscreening AT yanpeisha evaluatingtheperformanceofp16ink4aimmunocytochemistryincervicalcancerscreening AT liuzhihong evaluatingtheperformanceofp16ink4aimmunocytochemistryincervicalcancerscreening AT quxinfeng evaluatingtheperformanceofp16ink4aimmunocytochemistryincervicalcancerscreening AT belinsonjeromel evaluatingtheperformanceofp16ink4aimmunocytochemistryincervicalcancerscreening AT wuruifang evaluatingtheperformanceofp16ink4aimmunocytochemistryincervicalcancerscreening |